Remarkably, aspirin has been shown to amplify the effects of PD-L1 blockade in HCC Hepa 1–6 and H22 tumor models by directly acetylating FGL1, facilitating its degradation and offering a potential strategy to enhance HCC immunotherapy [78, 84]. The gene discussed is FGL1; the disease is hepatocellular carcinoma.